Clinical trial

Efficacy and Safety of CKD-501 Versus Pioglitazone When Added to Metformin

NCT01106131

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention CKD-501 0.5mg Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Pioglitazone 15mg Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Efficacy and Safety of CKD-501 Versus Pioglitazone When Added to Metformin

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2010-05-01

PhasePHASE3

Conditions

Type 2 Diabetes Mellitusverified · MONDO: type 2 diabetes mellitus

Interventions

CKD-501 0.5mgDRUG

Pioglitazone 15mgDRUG

Sponsors & collaborators

Chong Kun Dang Pharmaceuticallead sponsor

Mapped research locations

SeoulSouth Korea1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01106131 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.